Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers. The rate-limiting step in TTR amyloidogenesis is the dissociation of the TTR tetramer into monomers: Tafamidis is an effective TTR-stabilizer in its native homotetrameric structure. Tafamidis is a safe and effective drug in reducing symptoms, hospitalization and mortality in accurately selected patients affected by hereditary and wild-type transthyretin amyloid cardiomyopathy.
Copyright © 2024 Elsevier Inc. All rights reserved.
Overview publication
| Title | Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones. |
| Date | 2024-07-01 |
| Issue name | Heart failure clinics |
| Issue number | v20.3:333-341 |
| DOI | 10.1016/j.hfc.2024.03.007 |
| PubMed | 38844304 |
| Authors | |
| Keywords | ATTR, Amyloidoses, Cardiomyopathy, Tafamidis, Transthyretin, Treatment |
| Read | Read publication |